CELLULAR PROLIFERATION IN PROSTATIC ADENOCARCINOMA AS ASSESSED BY BROMODEOXYURIDINE UPTAKE AND KI-67 AND PCNA EXPRESSION

被引:77
作者
CHER, ML
CHEW, K
ROSENAU, W
CARROLL, PR
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT UROL,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT LAB MED,SAN FRANCISCO,CA 94143
关键词
NUCLEAR PROTEINS; TUMOR MARKERS; IMMUNOHISTOCHEMISTRY; PROGNOSIS;
D O I
10.1002/pros.2990260205
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prostatic carcinomas vary in their biological potential, even when stratified by grade and stage. Measurement of cellular proliferation by various methods has been shown to correlate with outcome for several human cancers, including prostatic carcinoma. Uptake of bromodeoxyuridine (BrdUrd), a thymidine analogue, has been accepted as a measure of cellular proliferative rate. However, the technique is somewhat complex, requiring incubation with fresh tissue. We compared cellular proliferation as measured by BrdUrd uptake with two more simple immunohistochemical methods in 44 prostatic adenocarcinoma specimens and correlated the results with standard clinical parameters. The tissue was obtained via needle biopsy, channel transurethral resection, and radical prostatectomy. Specimens were incubated in vitro with BrdUrd and then fixed and paraffin embedded. Sections were immunohistochemically stained with antibodies to BrdUrd, proliferating cell nuclear antigen (PCNA), and Ki-67. At least 1,000 cells were scored, and a labeling index (LI) was calculated (number of positive cells/total number of cells). The mean LI determined by all three indices was low (BrdUrd = 3.0, PCNA = 7.0, Ki-67 = 3.4), consistent with the knowledge that prostatic tumors grow slowly. In 36 patients who had not been treated at the time of analysis, the LI as determined by all three methods correlated well with clinical stage and pathological grade. Furthermore, the LIs discriminated between those with tumor confined to the prostate and those with extension to the seminal vesicles, lymph nodes, or bone (P = 0.003, 0.004, 0.008 for BrdUrd, PCNA, and Ki-67, respectively). The LIs for PCNA and Ki-67 correlated well with that for BrdUrd (r = 0.84; r = 0.85), while the LIs for Ki-67 and PCNA correlated slightly less well with each other (r = 0.78). PCNA and Ki-67 expression appear to reflect essentially the same biological process as BrdUrd uptake. Either can substitute for BrdUrd as a measure of cellular proliferation, and Ki-67 seems to offer the fewest technical problems. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 28 条
  • [1] KI67 IMMUNOSTAINING IN PRIMARY BREAST-CANCER - PATHOLOGICAL AND CLINICAL ASSOCIATIONS
    BOUZUBAR, N
    WALKER, KJ
    GRIFFITHS, K
    ELLIS, IO
    ELSTON, CW
    ROBERTSON, JFR
    BLAMEY, RW
    NICHOLSON, RI
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (06) : 943 - 947
  • [2] CELL-PROLIFERATION IN PROSTATIC ADENOCARCINOMA - INVITRO MEASUREMENT BY 5-BROMODEOXYURIDINE INCORPORATION AND PROLIFERATING CELL NUCLEAR ANTIGEN EXPRESSION
    CARROLL, PR
    WALDMAN, FM
    ROSENAU, W
    COHEN, MB
    VAPNEK, JM
    FONG, P
    NARAYAN, P
    MAYALL, BH
    [J]. JOURNAL OF UROLOGY, 1993, 149 (02) : 403 - 407
  • [3] MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS
    CATTORETTI, G
    BECKER, MHG
    KEY, G
    DUCHROW, M
    SCHLUTER, C
    GALLE, J
    GERDES, J
    [J]. JOURNAL OF PATHOLOGY, 1992, 168 (04) : 357 - 363
  • [4] EFFECT OF TAMOXIFEN ON KI67 LABELING INDEX IN HUMAN BREAST-TUMORS AND ITS RELATIONSHIP TO ESTROGEN AND PROGESTERONE-RECEPTOR STATUS
    CLARKE, RB
    LAIDLAW, IJ
    JONES, LJ
    HOWELL, A
    ANDERSON, E
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (03) : 606 - 611
  • [5] FLOW-CYTOMETRY AS A PREDICTIVE MODALITY IN PROSTATE-CANCER
    DEITCH, AD
    WHITE, RWD
    [J]. HUMAN PATHOLOGY, 1992, 23 (04) : 352 - 359
  • [6] MONOCLONAL-ANTIBODY KI-67 DEFINED GROWTH FRACTION IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC-CANCER
    GALLEE, MPW
    VISSERDEJONG, E
    TENKATE, FJW
    SCHROEDER, FH
    VANDERKWAST, TH
    [J]. JOURNAL OF UROLOGY, 1989, 142 (05) : 1342 - 1346
  • [7] PRODUCTION OF A MOUSE MONOCLONAL-ANTIBODY REACTIVE WITH A HUMAN NUCLEAR ANTIGEN ASSOCIATED WITH CELL-PROLIFERATION
    GERDES, J
    SCHWAB, U
    LEMKE, H
    STEIN, H
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1983, 31 (01) : 13 - 20
  • [8] GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
  • [9] RELATIONSHIP OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN PROSTATIC CARCINOMAS TO VARIOUS CLINICAL-PARAMETERS
    HARPER, ME
    GLYNNEJONES, E
    GODDARD, L
    WILSON, DW
    MATENHELIA, SS
    CONN, IG
    PEELING, WB
    GRIFFITHS, K
    [J]. PROSTATE, 1992, 20 (03) : 243 - 253
  • [10] PATHOLOGICAL AND CLINICAL ASSOCIATIONS OF KI-67 DEFINED GROWTH FRACTIONS IN HUMAN PROSTATIC-CARCINOMA
    HARPER, ME
    GODDARD, L
    WILSON, DW
    MATANHELIA, SS
    CONN, IG
    PEELING, WB
    GRIFFITHS, K
    [J]. PROSTATE, 1992, 21 (01) : 75 - 84